Hajra Naz
Russian researchers claim that Enteromix, an mRNA cancer vaccine, demonstrated 100% efficacy in clinical trials and caused no significant adverse effects. The National Medical Research Radiological Centre and the Engelhardt Institute of Molecular Biology (EIMB) led the project, which reported limited clinical use at select oncology centres, pending final approval from the Ministry of Health.
Trial teams ran the vaccine in carefully monitored programs. They report trial participants avoided the severe side effects common with chemotherapy and radiation, such as hair loss, extreme fatigue, and organ damage. Physicians treating those patients describe the tolerance profile as markedly better than standard treatments.
You may also like to read: Do Airpods Cause Cancer?
Enteromix uses mRNA to prompt a patient’s cells to make proteins that match tumor markers. The immune system then recognizes those proteins and attacks malignant cells. Developers say the approach targets tumors while sparing healthy tissue, which helps patients complete treatment without the same level of toxicity.
Doctors deliver Enteromix by intramuscular injection. Clinicians expect the vaccine to help people with lung, breast, colorectal, and pancreatic cancers. They also note potential benefit for patients with hereditary risks like BRCA1/2 mutations and for tumors that resist chemotherapy.
Regulators must review broader data before national rollout. Researchers plan larger trials to confirm results across diverse populations. If those studies match current findings and approvals follow, Enteromix may expand treatment options and change how clinicians approach certain cancers.
